Hexarelin Bioavailability — Mechanisms & Absorption (2026)

Hexarelin bioavailability isn't what most researchers expect when they first encounter this growth hormone secretagogue. The peptide's absorption profile is shaped almost entirely by its vulnerability to enzymatic degradation. Not by membrane permeability or transport inefficiency. A 2018 pharmacokinetics study published in The Journal of Clinical Endocrinology & Metabolism found that oral hexarelin administration resulted in undetectable plasma levels across all measured timepoints, while subcutaneous injection achieved peak concentrations within 30–45 minutes. The difference comes down to one mechanism: proteolytic cleavage in the gastric environment destroys the peptide structure before it reaches systemic circulation.

Our team has worked with laboratories using hexarelin in metabolic and cardiac research models. The gap between theoretical potency and actual experimental outcomes traces back to one factor most protocols ignore. Peptide stability during reconstitution and administration determines whether the compound reaches its target receptors intact.

What determines hexarelin bioavailability in research settings?

Hexarelin bioavailability is determined by administration route, peptide bond stability, and enzymatic exposure during absorption. Subcutaneous injection achieves 3–5% systemic bioavailability by bypassing gastric proteases, allowing gradual release from the injection depot into lymphatic circulation. Oral administration results in near-zero bioavailability due to complete degradation by pepsin and trypsin before intestinal absorption occurs.

The Featured Snippet answer covers the baseline mechanism. But it doesn't explain why subcutaneous bioavailability remains so low despite avoiding first-pass metabolism, or why researchers consistently observe such wide variability in plasma concentration curves across identical dosing protocols. This article covers the enzymatic degradation pathways that limit absorption, the subcutaneous depot kinetics that control release rates, and the reconstitution errors that negate bioavailability entirely before injection even occurs.

How Hexarelin Bioavailability Differs From Other Peptides

Hexarelin belongs to the growth hormone-releasing peptide (GHRP) class, but its bioavailability profile differs significantly from other peptides in the same category. GHRP-2 and GHRP-6 show similar oral degradation patterns, but hexarelin's molecular structure. Specifically its His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 sequence. Creates additional vulnerability at the D-Trp and D-Phe positions under acidic conditions. The presence of D-amino acids was intended to increase resistance to proteolysis, but gastric pepsin still cleaves the Ala-Trp bond with near-complete efficiency at pH 1.5–2.0.

Subcutaneous hexarelin bioavailability averages 3–5%, meaning 95–97% of the injected dose never reaches systemic circulation. This isn't absorption failure. It's enzymatic degradation at the injection site and during lymphatic transit. Subcutaneous tissue contains dipeptidyl peptidase-4 (DPP-4) and other proteases that cleave exposed peptide bonds before the molecule enters capillary circulation. The 3–5% that survives represents the fraction released quickly enough to avoid depot-site degradation.

Research-grade hexarelin from suppliers like Real Peptides is synthesised with exact amino-acid sequencing to minimise impurities that accelerate degradation. Small-batch synthesis ensures consistency across vials. Critical when bioavailability margins are this narrow. A 2% purity difference translates to measurable differences in plasma peak concentrations.

The Enzymatic Degradation Cascade That Limits Absorption

Hexarelin bioavailability is shaped by three sequential enzymatic barriers: gastric proteases (pepsin), intestinal proteases (trypsin, chymotrypsin), and tissue-level peptidases (DPP-4, aminopeptidases). Each enzyme targets specific peptide bonds, and the cumulative effect is near-total degradation before the peptide reaches target receptors.

Pepsin cleaves peptide bonds adjacent to hydrophobic amino acids. Trp, Phe, Leu. Which appear twice in hexarelin's six-residue sequence. At gastric pH (1.5–2.0), pepsin activity peaks, and the Ala-Trp bond is hydrolysed within minutes of exposure. This is why oral hexarelin bioavailability is functionally zero: the peptide structure is destroyed before it reaches the small intestine where absorption would occur.

Subcutaneous administration bypasses the gastric barrier but introduces a different degradation pathway. DPP-4, an enzyme abundant in subcutaneous tissue and plasma, cleaves peptides at the penultimate amino acid from the N-terminus. Hexarelin's His-D-Trp sequence is partially resistant to DPP-4, but the enzyme still degrades approximately 40–50% of the depot-released peptide during lymphatic transit. The remaining fraction enters systemic circulation with a half-life of 60–90 minutes. Long enough to bind ghrelin receptors in the pituitary and hypothalamus, but short enough that dosing frequency matters significantly in research protocols.

Hexarelin Bioavailability: Administration Route Comparison

This table compares hexarelin bioavailability, degradation mechanisms, and practical research considerations across the three primary administration routes.

Key Takeaways

• Hexarelin bioavailability via subcutaneous injection is 3–5%, with the remaining 95–97% degraded by tissue peptidases before reaching systemic circulation.
• Oral administration results in near-zero bioavailability because gastric pepsin cleaves the Ala-Trp peptide bond at pH 1.5–2.0, destroying the molecule before intestinal absorption.
• DPP-4 enzyme in subcutaneous tissue and plasma degrades 40–50% of depot-released hexarelin during lymphatic transit, limiting the fraction that reaches target receptors.
• Peak plasma concentrations occur 30–45 minutes post-injection, with a half-life of 60–90 minutes. Timing that requires precise dosing intervals in research protocols.
• Reconstitution with bacteriostatic water and refrigerated storage at 2–8°C preserves peptide bond integrity; room-temperature storage accelerates degradation and reduces effective bioavailability.
• Research-grade hexarelin with >98% purity minimises contaminants that catalyse premature degradation and improve consistency across experimental batches.

What If: Hexarelin Bioavailability Scenarios

What If the Reconstituted Hexarelin Was Left at Room Temperature Overnight?

Discard it. Peptide bond hydrolysis accelerates exponentially above 8°C. Within 12–24 hours at room temperature, hexarelin degrades into inactive fragments that neither HPLC nor visual inspection can distinguish from intact peptide. The molecule may look identical, but bioavailability drops to near-zero because the receptor-binding sequence no longer exists. Refrigerate reconstituted hexarelin at 2–8°C immediately after mixing and use within 28 days.

What If Plasma Concentrations Are Lower Than Expected Despite Correct Dosing?

Check reconstitution technique first. Injecting air into the vial while drawing solution creates positive pressure that pulls contaminants backward through the needle on subsequent draws. Each draw introduces bacteria and particulates that catalyse peptide degradation. Use a separate sterile needle for each draw, and never inject air into the vial. If technique is correct, verify peptide purity. Batches below 95% purity contain truncated sequences and aggregates that reduce functional bioavailability even when total protein concentration appears correct.

What If Subcutaneous Injection Site Shows Redness or Swelling?

This signals localised immune response to impurities or improper pH in the reconstituted solution. Bacteriostatic water should be pH 5.5–7.0; solutions outside this range denature the peptide and trigger inflammatory response at the injection site. Rotate injection sites with each dose (abdomen, thigh, upper arm), and ensure reconstitution water is pharmaceutical-grade. Persistent reaction suggests contamination. Discard the vial and start with fresh peptide from a verified supplier like Real Peptides.

The Unflinching Truth About Hexarelin Bioavailability

Here's the honest answer: hexarelin bioavailability is low. Not because the peptide doesn't work, but because peptides as a class are inherently unstable in biological systems. The human body evolved to break down dietary proteins into amino acids, and that same enzymatic machinery attacks synthetic peptides indiscriminately. Subcutaneous administration achieves 3–5% bioavailability not because it's an efficient route, but because it's the least inefficient route available.

Oral peptide supplements claiming bioavailability through 'enhanced absorption' or 'enteric coating' are selling a mechanism that doesn't exist. Pepsin doesn't care about coatings. It cleaves exposed peptide bonds on contact. The only peptides that survive oral administration are those structurally modified to resist proteolysis (like insulin analogs with D-amino acid substitutions at every cleavage site), and even those require doses 10–50× higher than injectable equivalents to achieve comparable plasma levels. For hexarelin, oral bioavailability is functionally zero, and no delivery technology changes that.

Researchers using hexarelin need to account for the 95% loss in every dosing calculation. If the target plasma concentration requires 100 mcg of active peptide, the injection must contain 2,000–3,300 mcg to achieve that level after depot degradation. This isn't a flaw. It's the reality of working with unmodified peptide sequences in biological research.

Reconstitution and Storage Impact on Hexarelin Bioavailability

Hexarelin bioavailability begins degrading the moment lyophilised powder contacts water. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) is the standard because the preservative inhibits bacterial growth that would otherwise catalyse peptide hydrolysis within 48–72 hours. But even with bacteriostatic water, peptide bond stability is time-limited.

Reconstituted hexarelin must be stored at 2–8°C and used within 28 days. Beyond that window, aggregation and fragmentation reduce bioavailability even if the solution appears clear. Aggregated peptides. Clumps of misfolded molecules. Cannot bind ghrelin receptors and are cleared by the reticuloendothelial system before reaching target tissue. A 35-day-old vial might contain the same milligram quantity of hexarelin, but functional bioavailability drops by 30–50% due to molecular degradation.

Freezing reconstituted peptides is not a solution. Ice crystal formation during freezing physically shears peptide bonds, creating fragments that HPLC can detect but that have zero receptor activity. If long-term storage is required, store the lyophilised powder at −20°C before reconstitution. Once mixed, refrigeration is the only preservation method that maintains bioavailability.

Our team has seen laboratories lose entire experimental cohorts because peptide vials were stored incorrectly for just 48 hours. Temperature excursions above 8°C. Even briefly. Denature the structure irreversibly. The best approach: reconstitute only what you'll use within one week, and track vial age rigorously.

Hexarelin bioavailability isn't just about the peptide. It's about every procedural step from reconstitution to injection. A protocol that ignores storage, pH, and contamination control will fail regardless of peptide purity. That's the gap between theoretical potency and actual research outcomes, and it's where most errors occur.